Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice

In summary, the treatment of EAE mice with the cannabinoid agonist WIN55,512-2 reduced their neurological disability and the progression of the disease. This effect was exerted through the activation of CB(1) receptors, which would exert a positive influence in the reduction of inflammatory events linked to the pathogenesis of this disease.

This information is for EDUCATIONAL PURPOSES only, not for diagnosing or treating any medical condition.